Psychopharmacology & biological narcologyPsychopharmacology & biological narcology1606-81812070-5670Eco-Vector32161910.17816/phbn321619Review ArticleExperimental treatment of induced fetal retardation in model animalsBespalovaOlesya N.<p>MD, Dr. Sci. (Med.)</p>shiggerra@mail.ruhttps://orcid.org/0000-0002-6542-5953BlazhenkoAleksandra A.<p>junior research assistant</p>alexandrablazhenko@gmail.comhttps://orcid.org/0000-0002-8079-0991The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott1105202314115222403202324032023Copyright © 2023, Eco-Vector2023<p>Intrauterine retardation is one of the major complications of pregnancy. This pathology occurs in approximately 10% of all pregnancies in developed countries and 20% in developing countries. Moreover, intrauterine retardation is more frequently associated with stillbirths than other pathologies. Despite studies conducted in the past 50 years, no generally accepted therapeutic regimen has yet been developed. Numerous drugs have been used for treatment; however, none of them has been proven effective. Moreover, after years of testing, new data are emerging about the side effects of the drugs previously used.</p>
<p>Various models of fetal retardation have been developed throughout the study of this problem. The main model animals are rats, pigs, and sheep. Numerous techniques and drug options have been proposed for the treatment of simulated intrauterine developmental delays in these animals. The main amino acids used for treatment were arginine, glutamine, taurine, and citrulline. Thus, the literature review aimed to analyze which model animals and experimental models of intrauterine retardation treatment most adequately reflect the effectiveness of these drugs.</p>intrauterine developmental delayplacental insufficiencycomparative biologyamino acidsзадержка внутриутробного развитияплацентарная недостаточностьсравнительная биологияаминокислоты[Barker DJP, Thornburg KL. Placental programming of chronic diseases, cancer and lifespan: A review. Placenta. 2013;34(10):841–845. DOI: 10.1016/j.placenta.2013.07.063][Barry JS, Rozance PJ, Anthony RV. An Animal Model of Placental Insufficiency-Induced Intrauterine Growth Restriction. Semin Perinatol. 2008;32(3):225–230. DOI: 10.1053/j.semperi.2007.11.004][von Beckerath AK, Kollmann M, Rotky-Fast C, et al. Perinatal complications and long-term neurodevelopmental outcome of infants with intrauterine growth restriction. Am J Obstet Gynecol. 2013;208(2):130.e1–130.e6. DOI: 10.1016/j.ajog.2012.11.014][Beune IM, Pels A, Gordijn SJ, Ganzevoort W. Temporal variation in definition of fetal growth restriction in the literature. Ultrasound Obstet Gynecol. 2019;53(5):569–570. DOI: 10.1002/uog.19189][Bourdon A, Parnet P, Nowak C, et al. L-citrulline supplementation enhances fetal growth and protein synthesis in rats with intrauterine growth restriction. J Nutr. 2016;146(3):532–541. DOI: 10.3945/jn.115.221267][Chen Y-H, Xu D-W, Wang J-P, et al. Melatonin protects against lipopolysaccharide-induced intra-uterine fetal death and growth retardation in mice. J Pineal Res. 2006;40(1):40–47. DOI: 10.1111/j.1600-079X.2005.00274.x][Clark PA, Brown JL, Li S, et al. Distal-less 3 haploinsufficiency results in elevated placental oxidative stress and altered fetal growth kinetics in the mouse. Placenta. 2012;33(10):830–838. DOI: 10.1016/j.placenta.2012.06.018][Eremia SC, de Boo HA, Bloomfield FH, et al. Fetal and amniotic insulin-like growth factor-I supplements improve growth rate in intrauterine growth restriction fetal sheep. Endocrinology. 2007;148(6):2963–2972. DOI: 10.1210/en.2006-1701][Figueras F, Gratacós E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. 2014;36(2):86–98. DOI: 10.1159/000357592][Wu G, Bazer FW, Wallace JM, Spencer TE. Board-invited review: intrauterine growth retardation: implications for the animal sciences. J Anim Sci. 2006;84(9):2316–2337. DOI: 10.2527/jas.2006-156][Wu G, Bazer FW, Tou W. Developmental changes of free amino acid concentrations in fetal fluids of pigs. J Nutr. 1995;125(11):2859–2868. DOI: 10.1093/jn/125.11.2859][Gu W, Morris SM. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336(1):1–17. DOI: 10.1042/bj3360001][Kwon H, Ford SP, Bazer FW, et al. Maternal nutrient restriction reduces concentrations of amino acids and polyamines in ovine maternal and fetal plasma and fetal fluids. Biol Reprod. 2004;71(3):901–908. DOI: 10.1095/biolreprod.104.029645][Herrera EA, Alegría R, Farias M, et al. Assessment of in vivo fetal growth and placental vascular function in a novel intrauterine growth restriction model of progressive uterine artery occlusion in guinea pigs. J Physiol. 2016;594(6):1553–1561. DOI: 10.1113/JP271467][Hou N, Liu Y, Han F, et al. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice. J Mol Cell Cardiol. 2016;99:188–196. DOI: 10.1016/j.yjmcc.2016.09.005][Keswani SG, Balaji S, Katz AB, et al. Intraplacental gene therapy with Ad-IGF-1 corrects naturally occurring rabbit model of intrauterine growth restriction. Hum Gene Ther. 2015;26(3):172–182. DOI: 10.1089/hum.2014.065][Liu J, Liu L, Chen H. Antenatal taurine supplementation for improving brain ultrastructure in fetal rats with intrauterine growth restriction. Neuroscience. 2011;181:265–270. DOI: 10.1016/j.neuroscience.2011.02.056][Lord VM, Reiboldt W, Gonitzke D, et al. Experiences of recovery in binge-eating disorder: A qualitative approach using online message boards. Eating and Weight Disorders. 2018;23(1):95–105. DOI: 10.1007/s40519-016-0335-z][Miller SL, Yawno T, Alers NO, et al. Antenatal antioxidant treatment with melatonin to decrease newborn neurodevelopmental deficits and brain injury caused by fetal growth restriction. J Pineal Res. 2014;56(3):283–294. DOI: 10.1111/jpi.12121][Morrison JL. Sheep models of intrauterine growth restriction: Fetal adaptations and consequences. Clin Exp Pharmacol Physiol. 2008;35(7):730–743. DOI: 10.1111/j.1440-1681.2008.04975.x][Resnik R. Intrauterine growth restriction. Obstet Gynecol. 2002;99(3):490–496. DOI: 10.1097/00006250-200203000-00020][Sano T, Terai Y, Daimon A, et al. Recombinant human soluble thrombomodulin as an anticoagulation therapy improves recurrent miscarriage and fetal growth restriction due to placental insufficiency – The leading cause of preeclampsia. Placenta. 2018;65:1–6. DOI: 10.1016/j.placenta.2018.03.006][Schröder HJ. Models of fetal growth restriction. Eur J Obstet Gynecol Reprod Biol. 2003;110(S):S29–S39. DOI: 10.1016/S0301-2115(03)00170-2][Sugimura Y, Murase T, Oyama K, et al. Prevention of neural tube defects by loss of function of inducible nitric oxide synthase in fetuses of a mouse model of streptozotocin-induced diabetes. Diabetologia. 2009;52(5):962–971. DOI: 10.1007/s00125-009-1312-0][Swanson AM, David AL. Animal models of fetal growth restriction: Considerations for translational medicine. Placenta. 2015;36(6): 623–630. DOI: 10.1016/j.placenta.2015.03.003][Tchirikov M, Kharkevich O, Steetskamp J, et al. Treatment of growth-restricted human fetuses with amino acids and glucose supplementation through a chronic fetal intravascular perinatal port system. Eur Surg Res. 2010;45(1):45–49. DOI: 10.1159/000318859][Tchirikov M, Zhumadilov ZSh, Bapayeva G, et al. The effect of intraumbilical fetal nutrition via a subcutaneously implanted port system on amino acid concentration by severe IUGR human fetuses. J Perinat Med. 2017;45(2):227–236. DOI: 10.1515/jpm-2016-0155][Terstappen F, Spradley FT, Bakrania BA, et al. Prenatal sildenafil therapy improves cardiovascular function in fetal growth restricted offspring of dahl salt-sensitive rats. Hypertension. 2019;73(5): 1120–1127. DOI: 10.1161/HYPERTENSIONAHA.118.12454][Valenzuela I, Kinoshita M, van der Merwe J, et al. Prenatal interventions for fetal growth restriction in animal models: A systematic review. Placenta. 2022;126:90–113. DOI: 10.1016/j.placenta.2022.06.007][Garmashova NL. Placental circulation / Acad. Med. Sci. of the USSR. Leningrad: Medicine, 1967. 243 p. (In Russ.)][Garmashova NL. Introduction to perinatal medicine. Moscow: Medicine, 1978. 294 p. (In Russ.)][Garmashova NL. Konstantinova NN. Pathophysiological bases for the protection of human intrauterine development. Leningrad: Medicine, 1985. 159 p. (In Russ.)]